Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Calling AbbVie Inc. (NYSE:ABBV) one of his “absolute favorites” during the recent episode of Mad Money, Cramer said: “Or how ...

Citigroup has reiterated its neutral stance on AbbVie, nudging its price target down from $210 to $205, despite the company’s ...

The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous ...

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including ...

Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis ...

The test detects the MET protein that is over-expressed in some patients with non-squamous non-small cell lung cancer.

Ironwood Pharmaceuticals, Inc.’s IRWD share price has dipped by 5.28%, which has investors questioning if this is right time to buy.

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...